|
Trade Name | Optune Lua |
Classification Name | electrical tumor treatment fields |
Generic Name | electrical tumor treatment fields |
Applicant |
Novocure, GmbH |
park 6 |
ch-6039 root d4 |
lucerne |
|
HDE Number | H180002 |
Date Received | 10/23/2018 |
Decision Date | 05/23/2019 |
Product Code | |
Docket Number | 19M-2522 |
Notice Date | 05/24/2019 |
Advisory Committee |
Anesthesiology |
Clinical Trials |
NCT02397928
|
Supplement Type | hde original |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for the novottf™-100l system. This device is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (mpm) to be used concurrently with pemetrexed and platinum-based chemotherapy. |
Approval Order | Approval Order |
Summary | Summary of Safety And Probable Benefit |
Labeling | Labeling Labeling Part 2 |
Supplements: |
S001 S002 S003 |